In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
FAQs
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Business Strategies Regulation

NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?

Executive Summary

NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?

You may also be interested in...



NicOx Blood Pressure Data Positive, But Is it Enough?

Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod

NicOx Data Positive, But Is it Enough?

NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.

NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

Table

View full table

Related Content

In Vivo
In Vivo
In Vivo
In Vivo

Topics

Related Companies

Tags:
BioPharmaceutical Business Strategies Regulation
UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By